Breast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year ...

Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM ...

The initiative is part of the company's efforts to expand the use of brain MRI technology across various healthcare settings.

LONDON, GREATER LONDON, UNITED KINGDOM, October 13, 2025 /EINPresswire.com/ -- Magnetic Resonance Imaging (MRI) Guided And Focused Ultrasound Devices Market Growth Forecast: What To Expect By 2025? In ...

TIANJIN -- The world's first magnetic resonance platform customized for brain-computer interface (BCI) technology was ...

Mass General Brigham AI and the University of Wisconsin–Madison will help to refine the company's latest foundational MRI ...

A study in the Journal of Orthopaedic Research uses a noninvasive, nonradioactive imaging-based method to measure the ...

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

The innovation, known as the continuous delivery of cryogen-free xenon system, enables scientists to produce and maintain ...

A study in the Journal of Orthopaedic Research uses a noninvasive, nonradioactive imaging-based method to measure the ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...